Your Search Results

Vulnerable plaque PCI after PREVENT

22 May 2025 – From EuroPCR 2025

This interview with Michael Haude and Thomas Cuisset explores findings from the PREVENT trial, which included over 1,600 patients with vulnerable, physiologically non-significant plaques identified by IVUS.

Patients were randomised to optimal medical therapy (OMT) alone or OMT plus preventive PCI. While the composite endpoint favoured the PCI...

Hotline - ACURATE neo2 under-expansion in the ACURATE IDE study: a post-hoc analysis

21 May 2025 – From EuroPCR 2025

Howard Herrmann and Raj Makkar discuss a sub-study of the ACURATE IDE trial, which examined valve under-expansion detected by fluoroscopy. Among 1,500 patients with aortic stenosis, 22 % of ACURATE neo2 valves showed under-expansion, often linked to heavy valve calcification.

Patients with under-expanded valves faced higher risks...

ACURATE neo2 under-expansion in the ACURATE IDE study: a post-hoc analysis

What are the essentials of the provisional strategy for non-left main true bifurcation lesions?

21 May 2025 – From EuroPCR 2025

Giuseppe Di Gioia and Jens Flensted Lassen explore the essentials of the provisional stenting strategy for non-left main true bifurcation lesions. This stepwise approach offers simplicity while preserving flexibility: start with one stent in the main vessel, and keep the option open for a second if...

What are the essentials of the provisional strategy for non-left main true bifurcation lesions?

How will EARLY-TAVI and NOTION-3 impact TAVI practice?

21 May 2025 – From EuroPCR 2025

When is the right time to perform TAVI—and how should coexisting coronary artery disease be managed? In this interview, Liesbeth Rosseel, Davide Capodanno, and Michael Joner tackle these two timely questions. They share key takeaways from the EARLY-TAVI trial, which demonstrated reduced rehospitalisation with early intervention...

How will EARLY-TAVI and NOTION-3 impact TAVI practice?

TAVI for aortic regurgitation in high surgical risk: outcomes in 700 patients from ALIGN-AR

12 Feb 2026 – From PCR London Valves 2025

Christopher Allen and Raj Makkar sit down to review the ALIGN-AR trial and its implications for treating native aortic regurgitation.

ALIGN-AR was a pivotal, single-arm, multicenter investigational study designed to evaluate a dedicated transcatheter solution in patients with moderate-to-severe native AR who were considered high risk for...

Outcomes in 700 patients from ALIGN-AR regarding TAVI for AR in high surgical risk

One-year results from the ADALA trial

16 Nov 2025 – From PCR London Valves 2025

Left atrial appendage (LAA) closure is a new focus at this year’s PCR London Valves Course, and, in this interview, Xavier Freixa and Christopher Allen discuss the ADALA trial and its impact on post-occlusion management.

The study compared three months of low-dose DOAC with three months of...

PARTNER 3 — 7-year follow-up: what it means for low-risk patients

16 Nov 2025 – From PCR London Valves 2025

Philippe Généreux and Philippe Pibarot discuss the long-term findings from PARTNER 3 and their practical implications for patient care.

They review the 7-year comparison of transfemoral TAVR versus surgical aortic-valve replacement in symptomatic patients with severe aortic stenosis who are at low surgical risk, and why the...

PARTNER 3 — 7-year follow-up: what it means for low-risk patients

TARGET study interim results: safety and performance of Cardiovalve replacement system for tricuspid regurgitation

16 Nov 2025 – From PCR London Valves 2025

Georg Nickenig and Christopher Allen discuss transcatheter replacement for the tricuspid valve and a dedicated transfemoral device in this interview, focusing on the TARGET study.

TARGET set out to answer two questions: can tricuspid regurgitation (TR) be reduced to mild or zero, and what are the safety...

TARGET study interim results: safety and performance of Cardiovalve replacement system for tricuspid regurgitation

How to successfully approach calcified bifurcation lesions?

20 May 2025 – From EuroPCR 2025

Calcified bifurcation lesions remain one of the toughest challenges in interventional cardiology, combining two high-risk features into one complex scenario.

In this discussion, Dejan Milasinovic, Miroslaw Ferenc, and Mohamed Abdel Wahab explain why this subset deserves dedicated attention. They highlight the critical role of intra-coronary imaging to...

How to successfully approach calcified bifurcation lesions?

How to successfully approach CTO interventions: a step-by-step approach

22 Oct 2025 – From EuroPCR 2025

Elliot Smith, Thomas Hovasse and Roberto Garbo discuss a comprehensive, step-by-step approach to CTO interventions, providing structured guidance on navigating CTOs in a safe and effective way.

The discussion begins with angiographic assessment, emphasising the importance of identifying key anatomical features upfront. Based on this evaluation, operators determine...

How to successfully approach CTO interventions: a step-by-step approach

Early treatment of severe aortic stenosis: do we need to wait?

20 May 2025 – From EuroPCR 2025

Rahul Sharma and Darren Walters share their perspectives on shifting treatment strategies for aortic stenosis (AS), with a focus on early intervention.

Their conversation draws on the EARLY TAVR trial, which compared transcatheter aortic valve replacement (TAVR) to clinical surveillance in patients with severe, asymptomatic AS at low surgical...

Early treatment of severe aortic stenosis: do we need to wait?

Five-year outcomes following early experience with transapical TMVR

16 Nov 2025 – From PCR London Valves 2025

In this discussion, Christopher Allen and Michael Reardon review the five-year results of an early transapical TMVR system implanted in very high-risk, inoperable patients.

The device showed sustained elimination of mitral regurgitation, with over 80% of patients maintaining trace or no MR at five years and no...